Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
European Journal of Medical Research
Published in: European Journal of Medical Research 1/2023

Open Access 01-12-2023 | Prostate Cancer | Research

Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years

Authors: Hanfei Zhang, Liu Xiao, Hangyu Xie, Lin Li

Published in: European Journal of Medical Research | Issue 1/2023

Login to get access

Abstract

Background

Prostate-specific membrane antigen (PSMA)-targeted imaging and therapy have significantly changed the management of patients with prostate cancer (PCa) at different disease stages. This advancement has attracted the attention of scholars, leading to a prolific output of scholarly publications. This study comprehensively outlines the knowledge framework associated with PSMA-based diagnosis and treatment of PCa through the application of bibliometric analysis, and discusses the potential research trends and foci.

Methods

Articles and reviews related to PSMA for prostate cancer from 2003 to 2022 were retrieved from Web of Science Core Collection. VOSviewer, Citespace, and R-bibliometrix were primarily employed to execute and visually represent co-authorship, co-citation, and co-occurrence analysis of countries, institutions, authors, references and keywords in this field.

Results

A total of 3830 papers were included. The papers on the field of PSMA-based PCa therapy and imaging had been continuously increased since 2003, but the rate has slowed from 2020. The United States made the largest contribution in this field, in terms of publications 997 (26.03%), H-index (110) and total citations (53,167 times). We identified the most productive institution were Technical University of Munich, and Australian institutions had become very active in recent years. Journal of Nuclear Medicine was the most prominent journal in this field. Professors Matthias Eiber and Martin G Pomper made great achievements, while Ali Afshar-Oromieh was the most co-cited author. According to the result of keywords and topics analysis, “ga-68 labeled psma ligand”, “radiation dosimetry” and “HBED-CC” were major research areas in the near future, while "Extended pelvic lymph node dissection" was considered to be the future research foci.

Conclusions

The field of psma-based PCa therapy and imaging is in the stage of vigorous development and has a bright prospect. The United States and Germany have achieved outstanding results in this area, while Australia has recently developed rapidly. It is foreseeable that more research foci will be lied in the early detection of pelvic lymph nodes and the multimodal imaging-guided surgery.
Appendix
Available only for authorised users
Literature
1.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.PubMedCrossRef
2.
3.
Hsing AW, Tsao L, Devesa SS. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer. 2000;85(1):60–7.PubMedCrossRef
4.
Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3(1):81–5.PubMed
5.
6.
Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res. 2009;15(2):167–72.PubMedCrossRef
7.
Fung EK, Cheal SM, Fareedy SB, Punzalan B, Beylergil V, Amir J, et al. Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI Res. 2016;6(1):7.PubMedPubMedCentralCrossRef
8.
9.
Czerwińska M, Bilewicz A, Kruszewski M, Wegierek-Ciuk A, Lankoff A. Targeted radionuclide therapy of prostate cancer-from basic research to clinical perspectives. Molecules. 2020;25(7):1743.PubMedPubMedCentralCrossRef
10.
El Fakiri M, Geis NM, Ayada N, Eder M, Eder AC. PSMA-targeting radiopharmaceuticals for prostate cancer therapy: recent developments and future perspectives. Cancers. 2021;13(16):3967.PubMedPubMedCentralCrossRef
11.
Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug Chem. 2011;22(10):1879–903.PubMedCrossRef
12.
Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56(11):1697–705.PubMedCrossRef
13.
Umbricht CA, Benešová M, Schmid RM, Türler A, Schibli R, van der Meulen NP, et al. (44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617-preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617. EJNMMI Res. 2017;7(1):9.PubMedPubMedCentralCrossRef
14.
Müller C, Domnanich KA, Umbricht CA, van der Meulen NP. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application. Br J Radiol. 2018;91(1091):20180074.PubMedPubMedCentralCrossRef
15.
Chen C. Science mapping: a systematic review of the literature. J Data Inf Sci. 2017;2:1–40.
16.
17.
18.
19.
van Eck NJ, Waltman L. Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics. 2010;84(2):523–38.PubMedCrossRef
20.
Synnestvedt MB, Chen C, Holmes JH. CiteSpace II: visualization and knowledge discovery in bibliographic databases. AMIA Annu Symp Proc. 2005;2005:724–8.PubMedPubMedCentral
21.
Chen C, Dubin R, Kim MC. Emerging trends and new developments in regenerative medicine: a scientometric update (2000–2014). Expert Opin Biol Ther. 2014;14(9):1295–317.PubMedCrossRef
22.
Eiber M, Maurer T, Souvatzoglou M, Beer AJ, Ruffani A, Haller B, et al. Evaluation of hybrid 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015;56(5):668–74.PubMedCrossRef
23.
Afshar-Oromieh A, Zechmann CM, Malcher A, Eder M, Eisenhut M, Linhart HG, et al. Comparison of PET imaging with a (68)Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2014;41(1):11–20.PubMedCrossRef
24.
Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, et al. PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4):486–95.PubMedCrossRef
25.
Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, et al. Sensitivity, specificity, and predictors of positive (68)Ga-prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;70(6):926–37.PubMedCrossRef
26.
Afshar-Oromieh A, Avtzi E, Giesel FL, Holland-Letz T, Linhart HG, Eder M, et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2015;42(2):197–209.PubMedCrossRef
27.
Banda A, Privé BM, Allach Y, Uijen MJM, Peters SMB, Loeff CC, et al. PSMA-RLT in patients with metastatic hormone-sensitive prostate cancer: a retrospective study. Cancers. 2022;15(1):297.PubMedPubMedCentralCrossRef
28.
Wu H, Xu T, Wang X, Yu YB, Fan ZY, Li DX, et al. Diagnostic performance of (68)gallium labelled prostate-specific membrane antigen positron emission tomography/computed tomography and magnetic resonance imaging for staging the prostate cancer with intermediate or high risk prior to radical prostatectomy: a systematic review and meta-analysis. World J Mens Health. 2020;38(2):208–19.PubMedCrossRef
29.
Uemura M, Watabe T, Hoshi S, Tanji R, Yaginuma K, Kojima Y. The current status of prostate cancer treatment and PSMA theranostics. Ther Adv Med Oncol. 2023;15:17588359231182292.PubMedPubMedCentralCrossRef
30.
31.
Shen Z, Hu J, Wu H, Chen Z, Wu W, Lin J, et al. Global research trends and foci of artificial intelligence-based tumor pathology: a scientometric study. J Transl Med. 2022;20(1):409.PubMedPubMedCentralCrossRef
32.
Foss CA, Mease RC, Fan H, Wang Y, Ravert HT, Dannals RF, et al. Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005;11(11):4022–8.PubMedCrossRef
33.
Rowe SP, Pomper MG. Molecular imaging in oncology: current impact and future directions. CA Cancer J Clin. 2022;72(4):333–52.PubMedCrossRef
34.
Rowe SP, Pienta KJ, Pomper MG, Gorin MA. PSMA-RADS version 1.0: a step towards standardizing the interpretation and reporting of psma-targeted pet imaging studies. Eur Urol. 2018;73(4):485–7.PubMedCrossRef
35.
Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650–9.PubMedPubMedCentralCrossRef
36.
Eiber M, Fendler WP, Rowe SP, Calais J, Hofman MS, Maurer T, et al. Prostate-specific membrane antigen ligands for imaging and therapy. J Nucl Med. 2017;58(Suppl 2):67s–76s.PubMedCrossRef
37.
Sterzing F, Kratochwil C, Fiedler H, Katayama S, Habl G, Kopka K, et al. (68)Ga-PSMA-11 PET/CT: a new technique with high potential for the radiotherapeutic management of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2016;43(1):34–41.PubMedCrossRef
38.
Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, et al. Diagnostic efficacy of (68)Gallium-PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. J Urol. 2016;195(5):1436–43.PubMedCrossRef
39.
Fendler WP, Calais J, Eiber M, Flavell RR, Mishoe A, Feng FY, et al. Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial. JAMA Oncol. 2019;5(6):856–63.PubMedPubMedCentralCrossRef
40.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825–33.PubMedCrossRef
41.
Bertagna F, Albano D, Giovanella L, Bonacina M, Durmo R, Giubbini R, et al. (68)Ga-PSMA PET thyroid incidentalomas. Hormones. 2019;18(2):145–9.PubMedCrossRef
42.
Rhee H, Blazak J, Tham CM, Ng KL, Shepherd B, Lawson M, et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 2016;6(1):76.PubMedPubMedCentralCrossRef
43.
Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018;169(3):447–55.PubMedCrossRef
44.
Kasoha M, Unger C, Solomayer EF, Bohle RM, Zaharia C, Khreich F, et al. Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases. Clin Exp Metastasis. 2017;34(8):479–90.PubMedCrossRef
45.
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, et al. Dosimetry of (177)Lu-PSMA-617 in metastatic castration-resistant prostate cancer: correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes. J Nucl Med. 2019;60(4):517–23.PubMedCrossRef
46.
Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals. 2021;14(8):13.CrossRef
47.
Benton DC, Watkins MJ, Beasley CJ, Ferguson SL, Holloway A. Evidence-based policy: nursing now and the importance of research synthesis. Int Nurs Rev. 2020;67(1):52–60.PubMedCrossRef
48.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79(2):243–62.PubMedCrossRef
49.
Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, et al. Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. Expert Rev Anticancer Ther. 2019;19(9):739–55.PubMedCrossRef
50.
Pathak RA, Hemal AK. Developing a personalized template for lymph node dissection during radical prostatectomy. Transl Androl Urol. 2018;7(Suppl 4):S498-s504.PubMedPubMedCentralCrossRef
51.
Marra G, Valerio M, Heidegger I, Tsaur I, Mathieu R, Ceci F, et al. Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review. Eur Urol Oncol. 2020;3(5):565–81.PubMedCrossRef
52.
Briganti A, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur Urol. 2006;50(5):1006–13.PubMedCrossRef
53.
Lenis AT, Pooli A, Lec PM, Sadun TY, Johnson DC, Lebacle C, et al. Prostate-specific membrane antigen positron emission tomography/computed tomography compared with conventional imaging for initial staging of treatment-naïve intermediate- and high-risk prostate cancer: a retrospective single-center study. Eur Urol Oncol. 2022;5(5):544–52.PubMedCrossRef
54.
Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395(10231):1208–16.PubMedCrossRef
55.
Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, et al. Can negative prostate-specific membrane antigen positron emission tomography/computed tomography avoid the need for pelvic lymph node dissection in newly diagnosed prostate cancer patients? A systematic review and meta-analysis with backup histology as reference standard. Eur Urol Oncol. 2022;5(1):1–17.PubMedCrossRef
56.
Maurer T, Robu S, Schottelius M, Schwamborn K, Rauscher I, van den Berg NS, et al. (99m)Technetium-based prostate-specific membrane antigen-radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;75(4):659–66.PubMedCrossRef
57.
Gondoputro W, Scheltema MJ, Blazevski A, Doan P, Thompson JE, Amin A, et al. Robot-assisted prostate-specific membrane antigen-radioguided surgery in primary diagnosed prostate cancer. J Nucl Med. 2022;63(11):1659–64.PubMedPubMedCentral
58.
Horn T, Krönke M, Rauscher I, Haller B, Robu S, Wester HJ, et al. Single lesion on prostate-specific membrane antigen-ligand positron emission tomography and low prostate-specific antigen are prognostic factors for a favorable biochemical response to prostate-specific membrane antigen-targeted radioguided surgery in recurrent prostate cancer. Eur Urol. 2019;76(4):517–23.PubMedCrossRef
59.
Lütje S, Heskamp S, Franssen GM, Frielink C, Kip A, Hekman M, et al. Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors. Theranostics. 2019;9(10):2924–38.PubMedPubMedCentralCrossRef
60.
Derks YHW, Rijpkema M, Amatdjais-Groenen HIV, Kip A, Franssen GM, Sedelaar JPM, et al. Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer. Theranostics. 2021;11(4):1527–41.PubMedPubMedCentralCrossRef
61.
Goerlandt F, Li J, Reniers G. The landscape of safety management systems research: A scientometric analysis. J Saf Sci Resil. 2022;3(3):189–208.
Metadata
Title
Hotspots and frontiers in PSMA research for prostate cancer: a bibliometric and visualization analysis over the past 20 years
Authors
Hanfei Zhang
Liu Xiao
Hangyu Xie
Lin Li
Publication date
01-12-2023
Publisher
BioMed Central
Published in
European Journal of Medical Research / Issue 1/2023
Electronic ISSN: 2047-783X
DOI
https://doi.org/10.1186/s40001-023-01590-w

Other articles of this Issue 1/2023

European Journal of Medical Research 1/2023 Go to the issue

Research

Stereotactic radiotherapy for brain metastases: predictive factors of radionecrosis

Research

Can radiologic parameters used to detect cervical spinal instability be used in patients with ankylosing spondylitis?

Research

Exploring the clinical application value of peripheral blood T lymphocyte subset in patients with asymptomatic omicron infection

Research

The association between air pollution and the daily hospital visits for atrial fibrillation recorded by ECG: a cross-sectional study

Research

Immune-associated biomarkers identification for diagnosing carotid plaque progression with uremia through systematical bioinformatics and machine learning analysis

Research

Analysis of the differential expression and prognostic relationship of DEGs in AML based on TCGA database